These lab-designed options were not created with recreational use in mind. In the 1990s, John W. Huffman and also a team of fellow chemists at Clemson University developed many of the very first formulation for synthetic cannabinoid receptor agonists (SCRAs), a family of substances that imitate the physiological and psychological impacts of cannabi